NCT04224480View on ClinicalTrials.gov

Longitudinal Immune-phenotyping of HCC Following MK-3475

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 10, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Pembrolizumab

200mg of intravenous infusion every 3 weeks

Trial Locations (1)

Unknown

National Cancer Centre Singapore, Singapore

All Listed Sponsors
collaborator

National Medical Research Council (NMRC), Singapore

OTHER_GOV

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

National Cancer Centre, Singapore

OTHER

NCT04224480 - Longitudinal Immune-phenotyping of HCC Following MK-3475 | Biotech Hunter | Biotech Hunter